人民财讯9月19日电，沃森生物(300142)9月19日公告，公司子公司北京沃森创新生物技术有限公司、云 南疫苗实验室有限公司、玉溪沃森生物技术有限公司联合复旦大学、上海蓝鹊生物医药有限公司联合研 发的冻干带状疱疹病毒mRNA疫苗向国家药品监督管理局申请临床试验，并于近日获得受理通知书。 转自：证券时报 ...

Group 1 - The core point of the article is that Watson Bio's subsidiary has had its clinical trial application for a freeze-dried herpes zoster virus mRNA vaccine accepted [1] Group 2 - The acceptance of the clinical trial application indicates progress in the development of innovative vaccine technology within the company [1] - This development could potentially enhance the company's position in the biopharmaceutical industry, particularly in the vaccine segment [1] - The mRNA vaccine technology is gaining traction globally, which may lead to increased interest and investment in similar projects [1]

Group 1 - The company, Zhaoyan New Drug (603127), announced an agreement with Industrial and Commercial Bank of China to subscribe to two wealth management products totaling RMB 40 million [1] - The total investment amount in these wealth management products, including those not yet redeemed as of the announcement date, is RMB 410 million [1]

Core Insights - The fifth China Biopharmaceutical Quality Control Conference highlighted the National Medical Products Administration's (NMPA) comprehensive reform of drug regulation, aimed at enhancing review and approval quality and efficiency, thereby stimulating innovation in the biopharmaceutical sector [1] Regulatory Developments - The NMPA plans to fully implement the State Council's opinions on deepening drug and medical device regulatory reforms to promote high-quality development in the pharmaceutical industry [1] - Future reforms will focus on improving the review and approval system, enhancing regulatory frameworks, and addressing clinical needs [1] Industry Growth - Among the 56 innovative drugs approved for market by 2025, 18 are biopharmaceutical products, indicating a significant presence of biopharmaceuticals in the innovation pipeline [1] - The NMPA aims to support the development of advanced therapeutic drugs and encourage companies to integrate into international innovation and supply chains, promoting high-quality growth in China's biopharmaceutical industry [1]

Market Overview - The biopharmaceutical sector experienced a decline of 1.9% on September 19, with Kanghong Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3820.09, down 0.3%, while the Shenzhen Component Index closed at 13070.86, down 0.04% [1] Stock Performance - Notable gainers included: - Aopumai (688293) with a closing price of 53.41, up 1.71% on a trading volume of 34,700 shares and a turnover of 189 million yuan [1] - Kexing Pharmaceutical (688136) closed at 41.88, up 1.70% with a trading volume of 45,300 shares and a turnover of 189 million yuan [1] - Significant decliners included: - Kanghong Pharmaceutical (002773) which fell 6.09% to a closing price of 37.00, with a trading volume of 94,100 shares and a turnover of 355 million yuan [2] - Changchun High-tech (000661) decreased by 3.91% to 125.22, with a turnover of 1.674 billion yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 999.7 million yuan from institutional investors, while retail investors had a net inflow of 914 million yuan [2] - The table of capital flow indicates that: - Changchun High-tech had a net inflow of 67.986 million yuan from institutional investors [3] - Kanghua Biological (300841) experienced a net inflow of 11.825 million yuan from institutional investors [3]

格隆汇9月19日丨欧林生物(688319.SH)公布，公司"重组多重耐药金黄色葡萄球菌疫苗研制与产业化"项 目入选四川省2025年第二批省级科技计划，公司于2025年9月19日收到政府补助款项共计人民币464万 元，其中324.8万元为公司所获政府补助；其余139.2万元为项目合作单位所获政府补助。本次收到的政 府补助将全部计入公司专项应付款科目，并按照相关规定根据项目后续完成及验收情况进行相应会计处 理。公司所获政府补助324.8万元均为与收益相关的政府补助。 ...

格隆汇9月19日丨欧林生物(688319.SH)公布，公司"重组多重耐药金黄色葡萄球菌疫苗研制与产业化"项 目入选四川省2025年第二批省级科技计划，公司于2025年9月19日收到政府补助款项共计人民币464万 元，其中324.8万元为公司所获政府补助；其余139.2万元为项目合作单位所获政府补助。本次收到的政 府补助将全部计入公司专项应付款科目，并按照相关规定根据项目后续完成及验收情况进行相应会计处 理。公司所获政府补助324.8万元均为与收益相关的政府补助。 ...

证券日报网讯 上海莱士9月18日在互动平台回答投资者提问时表示，公司董事会薪酬与考核委员会一直 密切关注公司高管薪酬体系的合理性与有效性，后续将持续优化薪酬考核体系，建立更为科学，并且符 合公司长远发展战略的薪酬激励机制。 （编辑 袁冠琳） ...

Summary of Key Points Core Viewpoint - The trading volume of the Shanghai and Shenzhen Stock Connect reached a total of 371.79 billion, with Industrial Fulian and CATL leading in individual stock trading volume. The biopharmaceutical sector saw the highest net inflow of funds, while the financial technology ETF experienced a significant increase in trading volume. Trading Volume - The total trading amount for the Shanghai Stock Connect was 175.90 billion, while the Shenzhen Stock Connect totaled 195.89 billion [1]. Top Trading Stocks - In the Shanghai Stock Connect, the top stocks by trading volume were: - Industrial Fulian: 4.73 billion - Haiguang Information: 4.57 billion - Huida Technology: 3.52 billion [2] - In the Shenzhen Stock Connect, the top stocks by trading volume were: - CATL: 4.83 billion - Zhongji Xuchuang: 3.47 billion - Luxshare Precision: 2.99 billion [2]. Sector Performance - The biopharmaceutical sector had the highest net inflow of funds at 588 million, followed by coal mining with 305 million. The non-bank financial sector saw the largest outflow at 19.87 billion [3][4]. ETF Trading - The top ten ETFs by trading volume included: - Hong Kong Securities ETF: 14.98 billion - Hang Seng Technology ETF: 14.11 billion - Hang Seng Technology Index ETF: 13.33 billion [6]. - The financial technology ETF Huaxia (516100) saw a remarkable increase in trading volume by 342% [7]. Futures Positioning - Major index futures contracts experienced significant reductions in both long and short positions as the delivery date approached, with the IM contract showing a larger decrease in short positions compared to long positions [8]. Institutional Activity - Notable institutional buying included: - Huafeng Technology: 1.25 billion - Chuanrun Co.: 673 million [9][10]. - Conversely, significant selling was observed in: - Dazhihui: 3.27 billion - Shanzi Gaoke: 1.62 billion [10]. Retail Investor Activity - Retail investors showed increased activity, particularly in Chuanrun Co. and Huafeng Technology, with substantial purchases recorded [12].

Market Overview - On September 18, the biopharmaceutical sector declined by 0.38%, with Kanghua Biotech leading the drop [1] - The Shanghai Composite Index closed at 3831.66, down 1.15%, while the Shenzhen Component Index closed at 13075.66, down 1.06% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Changchun High-tech: Closed at 130.31, up 5.19% with a trading volume of 233,800 shares and a turnover of 3.024 billion [1] - Zhifei Biological Products: Closed at 22.66, up 4.04% with a trading volume of 925,800 shares and a turnover of 2.12 billion [1] - ST Weiming: Closed at 8.88, up 3.26% with a trading volume of 182,300 shares and a turnover of 162 million [1] - Conversely, Kanghua Biotech experienced a significant decline, closing at 75.88, down 3.46% with a trading volume of 49,100 shares and a turnover of 381 million [2] Capital Flow - The biopharmaceutical sector saw a net inflow of 221 million from institutional investors, while retail investors experienced a net outflow of 340 million [2] - Key stocks with notable capital flows included: - Changchun High-tech: Net inflow of 353 million from institutional investors, with a net outflow of 283 million from retail investors [3] - Zhifei Biological Products: Net inflow of 10 million from institutional investors, with a net outflow of 125 million from retail investors [3] - Anke Bio: Net inflow of 64 million from institutional investors, with a net outflow of 877 million from retail investors [3]